Welcome to our dedicated page for Apogee Therapeutics SEC filings (Ticker: APGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
New drug data, milestone payments, and dilution risks hide deep inside every Apogee Therapeutics filing. For a clinical-stage biotech like Apogee Therapeutics Inc (APGE), 200-page reports packed with scientific jargon can slow critical decisions. If you have ever wondered, “Where do I locate Apogee Therapeutics insider trading Form 4 transactions before trial readouts?” or “How do I decode an S-1 packed with antibody engineering detail?”, Stock Titan turns that challenge into clarity.
Our platform delivers AI-powered summaries that make “understanding Apogee Therapeutics SEC documents with AI” a reality. Get instant context for every 8-K headline, see the numbers behind each “Apogee Therapeutics quarterly earnings report 10-Q filing,” and track cash flows without wading through footnotes. Real-time alerts surface “Apogee Therapeutics Form 4 insider transactions real-time,” while concise dashboards connect documentation to practical questions:
- “Apogee Therapeutics annual report 10-K simplified” – spot R&D spend and runway.
- “Apogee Therapeutics proxy statement executive compensation” – compare pay to pipeline progress.
- “Apogee Therapeutics 8-K material events explained” – assess data-readout impacts immediately.
Every filing type—10-K, 10-Q, 8-K, S-3, DEF 14A, and more—updates the moment EDGAR posts. Our expert layer highlights what the market watches most: partnership clauses, shelf-registration sizes, and “Apogee Therapeutics earnings report filing analysis” that links trial costs to cash on hand. Whether you are scanning “Apogee Therapeutics executive stock transactions Form 4” ahead of data releases or validating liquidity for the next antibody candidate, Stock Titan equips you to act decisively with filings explained simply.
Apogee Therapeutics, Inc. Chief Executive Officer and director Michael Henderson reported insider sales of common stock. On December 10, 2025, he sold a total of 20,000 shares of Apogee common stock in three transactions at weighted-average prices of $74.88, $75.79, and $76.58 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2025.
Following these sales, Henderson beneficially owns 1,212,987 shares of Apogee common stock directly. Some of the reported prices represent weighted averages for multiple trades executed within price ranges from $74.30 to $75.29 and from $75.30 to $76.28 per share, and he has agreed to provide detailed trade information to Apogee, any shareholder, or the SEC upon request.
Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, reported a sale of company stock. On December 4, 2025, he sold 10,900 shares of Apogee Therapeutics common stock at a weighted average price of about $75 per share, through multiple transactions between $75.00 and $75.01. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on August 21, 2024. After these sales, he directly beneficially owns 271,108 shares of Apogee Therapeutics common stock.
Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics (APGE) reported an insider transaction by its Chief Financial Officer, Jane Pritchett Henderson. On 11/11/2025, she sold 1,000 shares of common stock at $60 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 27, 2024. Following the sale, she beneficially owns 199,871 shares, held directly.
Apogee Therapeutics (APGE) filed a Form 4 reporting insider sales by CEO and director Michael Henderson. On 11/13/2025, he sold a total of 20,000 shares in four transactions executed under a Rule 10b5-1 trading plan adopted on August 13, 2025.
Weighted average prices were $61.93 (range $61.45–$62.39), $63.14 (range $62.50–$63.47), $63.89 (range $63.52–$64.39), and $64.52. Following these sales, Henderson directly beneficially owns 1,272,987 shares.
Apogee Therapeutics (APGE) filed its Q3 2025 report, showing a net loss of $65.0 million, driven by operating expenses of $71.3 million. Research and development was $54.2 million and general and administrative was $17.1 million. Interest income contributed $6.3 million.
Liquidity remained strong with cash and cash equivalents of $107.9 million, marketable securities of $419.4 million, and long-term marketable securities of $61.6 million as of September 30, 2025. The company recorded stockholders’ equity of $586.3 million and an accumulated deficit of $492.4 million. Management states these resources will fund operations for at least the next 12 months. Capital actions included $19.4 million of net proceeds from the at-the-market program in Q3 and, subsequently, approximately $324.1 million of net proceeds from an October 2025 underwritten offering of common stock and pre-funded warrants. As of November 3, 2025, shares outstanding were 68,320,229, including 54,833,587 voting and 13,486,642 non-voting shares.
Apogee Therapeutics (APGE) furnished an 8‑K noting two updates. The company issued an earnings press release covering the quarter ended September 30, 2025, and separately announced positive interim Phase 1 results from a healthy volunteer trial of APG333.
The earnings release is furnished as Exhibit 99.1 and the clinical data release as Exhibit 99.2. Both exhibits are furnished, not filed, under the Exchange Act.
Apogee Therapeutics (APGE) reported insider activity by its Chief Medical Officer on 11/05/2025. The officer exercised 8,060 stock options at $22.86 and sold common shares in multiple open‑market transactions: 2,300 at $53.62, 2,200 at $54.83, 5,607 at $55.58, and 678 at $56.51.
Following these trades, the officer directly owned 282,008 common shares and held 153,565 derivative securities (options). The filing notes the sales were executed under a Rule 10b5‑1 trading plan adopted on August 21, 2024, with several prices reported as weighted averages across multiple executions.
Apogee Therapeutics (APGE)
FAQ
What is the current stock price of Apogee Therapeutics (APGE)?
What is the market cap of Apogee Therapeutics (APGE)?
